Author(s)

Bo Cao ¹, Xiaobo Hu ¹, Min Chen ², Mingfeng Shen ¹, Lan Xu ¹

Affiliation(s)

¹ Department of Clinical Pharmacy, Affiliated Ninth Hospital of Suzhou University, Suzhou, China
² Department of Cardiovascular Medicine, Affiliated Ninth Hospital of Suzhou University, Suzhou, China

Corresponding Author

Lan Xu

ABSTRACT

Background: Evidence on the safety and effectiveness of non-vitamin K antagonist oral anticoagulants (NOACs) in atrial fibrillation (AF) patients with cancer is rather limited, so we performed this meta-analysis to compare the efficacy and safety of NOACs with vitamin K antagonists (VKAs) in real-world patients with AF and cancer. Methods: The PubMed and Embase databases were searched up to June 2020 for eligible studies. Outputs were presented as risk ratios (RRs) and corresponding 95% confidence intervals (CIs) using a random-effects model. Results: A total of five observational studies involving 232,234 cancer patients with AF were included. Compared with VKAs, use of NOACs was associated with decreased risks of stroke or systemic embolism (RR, 0.79; 95% CI 0.69-0.90), is chaemic stroke (RR, 0.82; 95% CI, 0.72-0.93), venous thromboembolism (VTE) (RR, 0.28; 95% CI 0.14-0.53), all-cause death (RR, 0.57; 95% CI 0.50-0.64), major bleeding (RR, 0.60; 95% CI 0.51-0.72) and intracranial or gastrointestinal bleeding (RR, 0.61; 95% CI, 0.51-0.73). Conclusions: In this combined analysis of real-world observational studies, NOACs showed lower risks of stroke or systemic embolism, ischaemic stroke, VTE, all-cause death and reduced rates of major bleeding and intracranial or gastrointestinal bleeding compared to VKAs in patients with AF and cancer.

KEYWORDS

Atrial fibrillation, Cancer, Oral anticoagulants, Real-world, Meta-analysis

CITE THIS PAPER

Bo Cao, Xiaobo Hu, Min Chen, Mingfeng Shen, Lan Xu. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Cancer in Real World: Meta-Analysis of Retrospective Observational Studies. MEDS Clinical Medicine (2021) 2: 61-66. DOI: http://dx.doi.org/10.23977/medsc.2021.020112.

REFERENCES

[1] Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death
[2] in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. J Am Med Assoc 2003; 290: 1049–1056.
[3] O'Neal WT, Lakoski SG, Qureshi W, et al. Relation between cancer and atrial fibrillation (from the REasons for Geographic and Racial Differences in Stroke Study). Am J Cardiol 2015;115:1090-4.
[4] Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122(10):1712-1723.
[5] Chu G, Versteeg HH, Verschoor AJ, Trines SA, Hemels MEW, Ay C, et al. Atrial
[6] fibrillation and cancer – An unexplored field in cardiovascular oncology. Blood Rev 2019; 35: 59–67.
[7] Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet 2014; 383: 955–62.
[8] Yang, P., Zhu, D., Xu, X., Shen, W., Wang, C., Jiang, Y., ... & Wu, Q. (2019). Efficacy and safety of oral anticoagulants in atrial fibrillation patients with cancer-a network meta-analysis. Heart failure reviews, 1-9.
[9] Cavallari, I., Verolino, G., Romano, S., & Patti, G. (2020). Efficacy and safety of nonvitamin K oral anticoagulants in patients with atrial fibrillation and cancer: a study-level meta-analysis. Thrombosis and haemostasis, 120(02), 314-321.
[10] Deng, Y., Tong, Y., Deng, Y., Zou, L., Li, S., & Chen, H. (2019). Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta‐Analysis. Journal of the American Heart Association, 8(14), e012540.
[11] Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting: Meta-analysis Of Observational Studies
[12] in Epidemiology (MOOSE) group. J Am Med Assoc 2000; 283: 2008–2012.
[13] Kim, K., Lee, Y. J., Kim, T. H., Uhm, J. S., Pak, H. N., Lee, M. H., & Joung, B. (2018). Effect of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with newly diagnosed cancer. Korean Circulation Journal, 48(5), 406-417.
[14] Ording, A. G., Horváth‐Puhó, E., Adelborg, K., Pedersen, L., Prandoni, P., & Sørensen, H. T. (2017). Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population‐based cohort study. Cancer medicine, 6(6), 1165-1172.
[15] Sawant, A. C., Kumar, A., Mccray, W., Tetewsky, S., Parone, L., Sridhara, S., ... & Bhardwaj, A. (2019). Superior safety of direct oral anticoagulants compared to Warfarin in patients with atrial fibrillation and underlying cancer: a national veterans affairs database study. Journal of Geriatric Cardiology: JGC, 16(9), 706.
[16] Shah, S., Norby, F. L., Datta, Y. H., Lutsey, P. L., MacLehose, R. F., Chen, L. Y., & Alonso, A. (2018). Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood advances, 2(3), 200-209.
[17] Yasui, T., Shioyama, W., Oboshi, M., Oka, T., & Fujita, M. (2019). Oral anticoagulants in Japanese patients with atrial fibrillation and active cancer. Internal Medicine, 58(13), 1845-1849.

Sponsors, Associates, and Links

---

• Journal of Neurobiology and Genetics
  
  
• Medical Imaging and Nuclear Medicine
  
  
• Bacterial Genetics and Ecology
  
  
• Transactions on Cancer
  
  
• Journal of Biophysics and Ecology
  
  
• Journal of Animal Science and Veterinary
  
  
• Academic Journal of Biochemistry and Molecular Biology
  
  
• Transactions on Cell and Developmental Biology
  
  
• Rehabilitation Engineering & Assistive Technology
  
  
• Orthopaedics and Sports Medicine
  
  
• Hematology and Stem Cell
  
  
• Journal of Intelligent Informatics and Biomedical Engineering
  
  
• MEDS Basic Medicine
  
  
• MEDS Stomatology
  
  
• MEDS Public Health and Preventive Medicine
  
  
• MEDS Chinese Medicine
  
  
• Journal of Enzyme Engineering
  
  
• Advances in Industrial Pharmacy and Pharmaceutical Sciences
  
  
• Bacteriology and Microbiology
  
  
• Advances in Physiology and Pathophysiology
  
  
• Journal of Vision and Ophthalmology
  
  
• Frontiers of Obstetrics and Gynecology
  
  
• Digestive Disease and Diabetes
  
  
• Advances in Immunology and Vaccines
  
  
• Nanomedicine and Drug Delivery
  
  
• Cardiology and Vascular System
  
  
• Pediatrics and Child Health
  
  
• Journal of Reproductive Medicine and Contraception
  
  
• Journal of Respiratory and Lung Disease
  
  
• Journal of Bioinformatics and Biomedicine